1 Min Read
Sept 11 (Reuters) - Syros Pharmaceuticals Inc
* Syros pharmaceuticals - expects to present initial phase 2 clinical data for SY-1425 in Q4 of 2017 Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.